DOC
SLIDES
Featured
Recent
Articles
Topics
Upload
Login
Sign Up
Featured
Recent
Articles
Topics
Upload
Login
Sign Up
Home
›
Search Results for "tdf hiv"
Search Results for 'tdf hiv'
tdf hiv published presentations and documents on DocSlides.
Comparison of NNRTI vs NNRTI
by tatyana-admore
ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR...
Switch to EVG/c/FTC/TDF
by liane-varnes
STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Desi...
Fixed-Dose Combination of
by myesha-ticknor
Doravirine. /Lamivudine/TDF is Non-Inferior to . ...
1 Fundación Huésped, Buenos Aires, Argentina;
by aaron
2. Instituto Nacional de Ciencias Médicas y Nutr...
Comparison of NNRTI vs NNRTI
by lindy-dunigan
ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR...
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
by phoebe-click
ACTIVITY CODE . TD342. Antiretroviral Medications...
“On Demand” Oral PrEP: Lessons Learned from Macaque Models
by giovanna-bartolotta
“On Demand” Oral PrEP: Lessons Learned from M...
Gilead Sciences, Inc., Foster City, CA, USA
by phoebe-click
Gilead Sciences, Inc., Foster City, CA, USA FTC/T...
Phase 2 of new ARVs Fostemsavir
by sportyinds
, . prodrug. of . temsavir. . (. attachment inhi...
Comparison of RTV vs Cobi
by studmonkeybikers
GS-US-216-0114. . Gallant JE. JID 2013;208:32-9...
937401234123534671341849346744x 19 333133Webinar Requirements A c
by erica
HBcAbThis prescribe ARTART Dispensed0-5-14 Days0-1...
DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT
by jasmine
–. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RE...
Jeanne Marrazzo, MD, MPH
by rose
Professor of Medicine. University of Washington. S...
HIV 2020: Time for change
by garcia
Dr. Kay Mahomed. Netcare. Garden City Clinic. Ma...
Switching from TDF/FTC to TAF/
by fanny
FTC. Study 311-1089. Switching from TDF/FTC to TAF...
Cases from the Clinic(ians): Case-based Panel Discussion
by tripp
Associate Dean for Global Health. University of Al...
CROI 2015: HIV Prevention Updates
by pamella-moone
Ruanne V Barnabas, . MBChB. . Dphil. Global Heal...
ID Week 2016: HIV Update
by min-jolicoeur
Robert Harrington, M.D.. ID Week 2016: HIV Update...
Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazan
by sherrill-nordquist
± . Ritonavir. Carey Hwang. ,. 1. Dirk Schürma...
Track B Workshop Controversies in the Management of HIV-positive Adults:
by natalia-silvester
A Case-Based Approach. Sasisopin Kiertiburanakul,...
Essentials for Optimal Care of HIV Patients
by marina-yarberry
Evidence-Based Approaches. Simply Speaking. ®. ...
Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians)
by alida-meadow
Treating and Preventing HIV in 2019: Interactive ...
PrEP to Prevent HIV and Promote Sexual Health
by cheryl-pisano
PrEP to Prevent HIV and Promote Sexual Health www...
The Eras of the HIV Epidemic
by relylancome
1981-1986. 1987-1995. 1996-2005. 2006-2011. 2012+....
HIV PREVENTION SAMU SUMMARY
by FluffyFace
2018. Objectives . To describe the current situati...
HIV Transmission PrEP /
by PeacefulPlace
nPEP. Mark Schweizer, DDS MPH. Director Infection ...
Optimizing HIV treatment
by anderson
Professor Francois Venter. Ezintsha, University of...
Susan P. Buchbinder, MD Director, Bridge HIV
by harmony
San . Francisco Department . of Public Health. Cli...
Innovative Strategies for the Management
by karlyn-bohler
of HIV Infection. Dual therapies without NRTIs. J...
CDC’s Interim Guidance on the Use of PrEP in Heterosexual
by calandra-battersby
Adults:. . Implications . for Clinical Practice....
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...
Update on risk factors, detection, and management of neuroc
by natalia-silvester
Scott Letendre, M.D.. Professor of . Medicine and...
Highlights of AIDS
by calandra-battersby
2016: Advances in . HIV Prevention, Care and Trea...
Comparison of INSTI vs INSTI
by pamella-moone
QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Object...
PrEP Training for
by tatyana-admore
Providers in Clinical Settings. 2. Welcome!. Plea...
A Demonstration Open Label
by jane-oiler
Study to Assess the . Acceptability. , Safety. a...
ART for Prevention… What Happens Next?
by briana-ranney
Myron S. Cohen, MD. Yeargan-Bate Eminent Professo...
Characteristics and Oral
by lois-ondreau
PrEP. Adherence in the TDF2 Open-Label Extension...
ART in Resource-limited settings :
by liane-varnes
Progress and Challenges. Dr. B. B. . Rewari. MD,...
ADOLESCENT PrEP STUDIES
by min-jolicoeur
. . Shorai. . Mukaka. , . MBchB. ...
Load More...